Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cbd + thc-Johns Hopkins University
- Development stage
- Phase 3
- Lead developer
- Johns Hopkins University
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
cbd + thc-Johns Hopkins University refers to research-grade vaporized cannabis formulations containing delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) utilized in Phase 1 clinical trials by Johns Hopkins University's Behavioral Pharmacology Research Unit. These formulations are primarily used to evaluate the physiological and behavioral responses, including subjective drug effects and cognitive performance, in healthy occasional cannabis users. THC acts as a partial agonist at the cannabinoid CB1 and CB2 receptors, mediating psychoactive and analgesic effects, while CBD functions as a negative allosteric modulator of the CB1 receptor and interacts with various other targets such as 5-HT1A and TRPV1. The cannabis material for these studies is typically sourced from the National Institute on Drug Abuse (NIDA) Drug Supply Program. The research is designed for pharmacodynamic characterization in controlled laboratory settings rather than for the treatment of specific clinical indications.
- Other names
- vaporized CBD with THCvaporized THC and CBDcannabidiol + delta-9-tetrahydrocannabinol
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on cbd + thc-Johns Hopkins University.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cbd + thc-Johns Hopkins University.